ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Average Rating of "Buy" by Brokerages

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) has been assigned a consensus rating of "Buy" from the eight ratings firms that are presently covering the firm, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $8.00.

PRQR has been the topic of several recent analyst reports. Evercore ISI reaffirmed an "outperform" rating on shares of ProQR Therapeutics in a report on Friday, July 11th. Chardan Capital reaffirmed a "buy" rating and issued a $4.00 price target on shares of ProQR Therapeutics in a report on Friday, August 8th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $8.00 price target on shares of ProQR Therapeutics in a report on Friday, June 27th. JMP Securities reaffirmed a "market outperform" rating and issued a $8.00 price target on shares of ProQR Therapeutics in a report on Friday, June 27th. Finally, Oppenheimer cut their price target on shares of ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th.

ProQR Therapeutics Stock Performance

Shares of PRQR stock traded up $0.05 on Tuesday, hitting $2.26. The stock had a trading volume of 460,691 shares, compared to its average volume of 274,267. The firm has a market capitalization of $237.77 million, a price-to-earnings ratio of -4.91 and a beta of 0.43. The stock's 50 day moving average is $2.13 and its 200-day moving average is $1.87. ProQR Therapeutics has a 52-week low of $1.07 and a 52-week high of $4.62.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.06). The company had revenue of $4.33 million during the quarter, compared to analyst estimates of $5.01 million. ProQR Therapeutics had a negative net margin of 238.52% and a negative return on equity of 61.25%. Equities analysts expect that ProQR Therapeutics will post -0.31 earnings per share for the current year.

Institutional Trading of ProQR Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of PRQR. Adage Capital Partners GP L.L.C. raised its holdings in shares of ProQR Therapeutics by 164.9% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 9,602,280 shares of the biopharmaceutical company's stock worth $25,446,000 after purchasing an additional 5,976,813 shares during the period. Woodline Partners LP acquired a new stake in shares of ProQR Therapeutics during the fourth quarter worth $9,426,000. Millennium Management LLC raised its holdings in shares of ProQR Therapeutics by 1,864.4% during the fourth quarter. Millennium Management LLC now owns 2,827,280 shares of the biopharmaceutical company's stock worth $7,492,000 after purchasing an additional 2,683,351 shares during the period. Aberdeen Group plc acquired a new stake in shares of ProQR Therapeutics during the first quarter worth $2,461,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of ProQR Therapeutics during the fourth quarter worth $3,952,000. 32.65% of the stock is owned by institutional investors and hedge funds.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).